The Experts below are selected from a list of 171 Experts worldwide ranked by ideXlab platform
Kyong-mi Chang - One of the best experts on this subject based on the ideXlab platform.
-
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Journal of hepatology, 2019Co-Authors: Markus Cornberg, Anna S.f. Lok, Norah A. Terrault, Fabien Zoulim, Thomas Berg, Maurizia Rossana Brunetto, Stephanie Buchholz, Maria Buti, Henry Lik-yuen Chan, Kyong-mi ChangAbstract:Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary Goal of developing agreement on chronic HBV treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilising cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of phase III trials should be functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of response in these trials. Sustained virologic suppression (undetectable serum HBV DNA) without HBsAg loss 6 months after discontinuation of treatment would be an Intermediate Goal. Demonstrated validity for the prediction of sustained HBsAg loss was considered the most appropriate criterion for the approval of new HBV assays to determine efficacy endpoints. Clinical trials aimed at HBV functional cure should initially focus on patients with HBeAg-positive or negative chronic hepatitis, who are treatment-naïve or virally suppressed on nucleos(t)ide analogues. A hepatitis flare associated with an increase in bilirubin or international normalised ratio should prompt temporary or permanent cessation of an investigational treatment. New treatments must be as safe as existing nucleos(t)ide analogues. The primary endpoint for phase III trials for HDV coinfection should be undetectable serum HDV RNA 6 months after stopping treatment. On treatment HDV RNA suppression associated with normalisation of alanine aminotransferase is considered an Intermediate Goal. In conclusion, regarding HBV 'functional cure', the primary Goal is sustained HBsAg loss with undetectable HBV DNA after completion of treatment and the Intermediate Goal is sustained undetectable HBV DNA without HBsAg loss after stopping treatment.
Vincent Dru - One of the best experts on this subject based on the ideXlab platform.
-
age related differences in processes organizing Goal directed locomotion toward emotional pictures
Neuroscience, 2017Co-Authors: Sylvie Vernazzamartin, Lilian Fautrelle, Sophie Longuet, Sandrine Vieillard, Vincent DruAbstract:Abstract Previous studies yielded evidence for an interaction between age and valence in numerous cognitive processes. But, to date, no research has been conducted in the field of motor skills. In this study, we examined the age-related differences in the organization of an emotionally Goal-directed locomotion task. Faced with a pleasant, unpleasant, or neutral picture displayed to the side of a stop button, younger and older adults were instructed to walk toward the button (Intermediate Goal) and push it to turn-off the picture (final Goal). Kinematic and ground reaction forces were recorded. The main findings indicated that older adults’ response times (RTs) did not differ across the valence picture. The fastest RTs were found in younger adults when faced with pleasant pictures, suggesting that older people may focus either on Intermediate or final Goals, depending on their value of pleasantness, and prioritize positive Goals. We also found that the spatial coding of locomotion (trajectory and final body position) was affected in the same way by the valence of the Intermediate Goal in both age groups. Taken together, these findings provide new perspectives regarding the potential role of the emotional valence of the Intermediate and final Goals on the cognitive processes involved in action coding, such as in mental representations of action in older adults.
-
When locomotion is used to interact with the environment: investigation of the link between emotions and the twofold Goal-directed locomotion in humans.
Experimental brain research, 2015Co-Authors: Sylvie Vernazza-martin, Sophie Longuet, T. Damry, J. M. Chamot, Vincent DruAbstract:Walking as a means to interact with the environment has a twofold Goal: body displacement (Intermediate Goal) and the future action on the environment (final representational Goal). This involves different processes that plan, program, and control Goal-directed locomotion linked to motivation as an “emotional state,” which leads to achieving this twofold Goal. The aim of the present study was to determine whether emotional valence associated with the final representational Goal influences these processes or whether they depend more on the emotional valence associated with the Intermediate Goal in young adults. Twenty subjects, aged 18–35 years, were instructed to erase an emotional picture that appeared on a wall as soon as they saw it. They had to press a stop button located 5 m in front of them with their right hand. Their gait was analyzed using a force platform and the Vicon system. The main results suggest that the emotional valence of the Intermediate Goal has the greatest effect on the processes that organize and modulate Goal-directed locomotion. A positive valence facilitates cognitive processes involved in the temporal organization of locomotion. A negative valence disturbs the cognitive processes involved in the spatial organization of the locomotion and online motor control, leading to a deviating trajectory and a final body position that is more distant from the stop button. These results are discussed in line with the motivational direction hypothesis and with the affective meaning of the intended response Goal.
Ingo Krossing - One of the best experts on this subject based on the ideXlab platform.
-
The Ideal Ionic Liquid Salt Bridge for Direct Determination of Gibbs Energies of Transfer of Single Ions, Part II: Evaluation of the Role of Ion Solvation and Ion Mobilities.
Angewandte Chemie (International ed. in English), 2018Co-Authors: Andreas Ermantraut, Valentin Radtke, Niklas Gebel, Daniel Himmel, Thorsten Koslowski, Ivo Leito, Ingo KrossingAbstract:An important Intermediate Goal to evaluate our concept for the assumption-free determination of single-ion Gibbs transfer energies Δtr G°(i, S1 →S2 ) is presented. We executed the crucial steps a) and b) of the methodology, described in Part I of this treatise, exemplarily for Ag+ and Cl- with S1 being water and S2 being acetonitrile. The experiments showed that virtually all parts of the liquid junction potentials (LJPs) at both ends of a salt bridge cancel, if the bridge electrolyte is an "ideal" ionic liquid, that is, one with nearly identical diffusion of anion and cation. This ideality holds for [N2225 ]+ [NTf2 ]- in the pure IL, but also in water and acetonitrile solution. Electromotive force measurements of solvation cells between S1 and S2 demonstrated Nernstian behavior for Ag+ concentration cells and constant like cell potentials for solutions with five tested Ag+ counterions.
Markus Cornberg - One of the best experts on this subject based on the ideXlab platform.
-
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.
Hepatology (Baltimore Md.), 2019Co-Authors: Markus Cornberg, Anna S.f. Lok, Norah A. Terrault, Fabien ZoulimAbstract:Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary Goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilizing cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of phase 3 trials should be functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of response in these trials. Sustained virologic suppression (undetectable serum HBV DNA) without HBsAg loss, 6 months after discontinuation of treatment would be an Intermediate Goal. Demonstrated validity in predicting sustained HBsAg loss was considered the most appropriate criterion for the approval of new HBV assays to determine efficacy endpoints. Clinical trials aimed at HBV functional cure should initially focus on patients with HBeAg-positive and HBeAg-negative chronic hepatitis, treatment-naïve or virally suppressed on nucleos(t)ide analogues. A hepatitis flare associated with increase in bilirubin or INR should prompt temporary or permanent cessation of investigational treatment. New treatments must be as safe as existing nucleos(t)ide analogues. The primary endpoint for phase 3 trials for hepatitis D virus (HDV) co-infection should be undetectable serum HDV RNA 6 months after stopping treatment. On treatment HDV RNA suppression associated with normalization of ALT is considered an Intermediate Goal. CONCLUSION: For HBV 'functional cure', sustained HBsAg loss with undetectable HBV DNA after completion of treatment is the primary Goal and sustained undetectable HBV DNA without HBsAg loss after stopping treatment an Intermediate Goal.
-
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Journal of hepatology, 2019Co-Authors: Markus Cornberg, Anna S.f. Lok, Norah A. Terrault, Fabien Zoulim, Thomas Berg, Maurizia Rossana Brunetto, Stephanie Buchholz, Maria Buti, Henry Lik-yuen Chan, Kyong-mi ChangAbstract:Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary Goal of developing agreement on chronic HBV treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilising cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of phase III trials should be functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of response in these trials. Sustained virologic suppression (undetectable serum HBV DNA) without HBsAg loss 6 months after discontinuation of treatment would be an Intermediate Goal. Demonstrated validity for the prediction of sustained HBsAg loss was considered the most appropriate criterion for the approval of new HBV assays to determine efficacy endpoints. Clinical trials aimed at HBV functional cure should initially focus on patients with HBeAg-positive or negative chronic hepatitis, who are treatment-naïve or virally suppressed on nucleos(t)ide analogues. A hepatitis flare associated with an increase in bilirubin or international normalised ratio should prompt temporary or permanent cessation of an investigational treatment. New treatments must be as safe as existing nucleos(t)ide analogues. The primary endpoint for phase III trials for HDV coinfection should be undetectable serum HDV RNA 6 months after stopping treatment. On treatment HDV RNA suppression associated with normalisation of alanine aminotransferase is considered an Intermediate Goal. In conclusion, regarding HBV 'functional cure', the primary Goal is sustained HBsAg loss with undetectable HBV DNA after completion of treatment and the Intermediate Goal is sustained undetectable HBV DNA without HBsAg loss after stopping treatment.
Fabien Zoulim - One of the best experts on this subject based on the ideXlab platform.
-
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.
Hepatology (Baltimore Md.), 2019Co-Authors: Markus Cornberg, Anna S.f. Lok, Norah A. Terrault, Fabien ZoulimAbstract:Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary Goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilizing cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of phase 3 trials should be functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of response in these trials. Sustained virologic suppression (undetectable serum HBV DNA) without HBsAg loss, 6 months after discontinuation of treatment would be an Intermediate Goal. Demonstrated validity in predicting sustained HBsAg loss was considered the most appropriate criterion for the approval of new HBV assays to determine efficacy endpoints. Clinical trials aimed at HBV functional cure should initially focus on patients with HBeAg-positive and HBeAg-negative chronic hepatitis, treatment-naïve or virally suppressed on nucleos(t)ide analogues. A hepatitis flare associated with increase in bilirubin or INR should prompt temporary or permanent cessation of investigational treatment. New treatments must be as safe as existing nucleos(t)ide analogues. The primary endpoint for phase 3 trials for hepatitis D virus (HDV) co-infection should be undetectable serum HDV RNA 6 months after stopping treatment. On treatment HDV RNA suppression associated with normalization of ALT is considered an Intermediate Goal. CONCLUSION: For HBV 'functional cure', sustained HBsAg loss with undetectable HBV DNA after completion of treatment is the primary Goal and sustained undetectable HBV DNA without HBsAg loss after stopping treatment an Intermediate Goal.
-
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Journal of hepatology, 2019Co-Authors: Markus Cornberg, Anna S.f. Lok, Norah A. Terrault, Fabien Zoulim, Thomas Berg, Maurizia Rossana Brunetto, Stephanie Buchholz, Maria Buti, Henry Lik-yuen Chan, Kyong-mi ChangAbstract:Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary Goal of developing agreement on chronic HBV treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilising cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of phase III trials should be functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of response in these trials. Sustained virologic suppression (undetectable serum HBV DNA) without HBsAg loss 6 months after discontinuation of treatment would be an Intermediate Goal. Demonstrated validity for the prediction of sustained HBsAg loss was considered the most appropriate criterion for the approval of new HBV assays to determine efficacy endpoints. Clinical trials aimed at HBV functional cure should initially focus on patients with HBeAg-positive or negative chronic hepatitis, who are treatment-naïve or virally suppressed on nucleos(t)ide analogues. A hepatitis flare associated with an increase in bilirubin or international normalised ratio should prompt temporary or permanent cessation of an investigational treatment. New treatments must be as safe as existing nucleos(t)ide analogues. The primary endpoint for phase III trials for HDV coinfection should be undetectable serum HDV RNA 6 months after stopping treatment. On treatment HDV RNA suppression associated with normalisation of alanine aminotransferase is considered an Intermediate Goal. In conclusion, regarding HBV 'functional cure', the primary Goal is sustained HBsAg loss with undetectable HBV DNA after completion of treatment and the Intermediate Goal is sustained undetectable HBV DNA without HBsAg loss after stopping treatment.